Effects of exenatide on metabolic parameters/control in obese Japanese patients with type 2 diabetes

Endocrine Journal

Volumn 61, Issue 4, 2014, Pages 365-372

  Tokuda, Masaru ^a   Katsuno, Tomoyuki ^a   Ochi, Fumihiro ^a   Miyakoshi, Kana ^a   Kusunoki, Yoshiki ^a   Murai, Kazuki ^a   Miuchi, Masayuki ^a   Hamaguchi, Tomoya ^a   Miyagawa, Jun Ichiro ^a   Namba, Mitsuyoshi ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Exenatide; Incretin; Obesity; Type 2 diabetes mellitus

Indexed keywords

ALBUMIN; ALPHA GLUCOSIDASE INHIBITOR; C PEPTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIOBESITY AGENT; GASTROINTESTINAL AGENT; GLUCAGON LIKE PEPTIDE 1; HYPOCHOLESTEROLEMIC AGENT; PEPTIDE; VENOM;

ADULT; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DIET THERAPY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG WITHDRAWAL; EXERCISE; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HORMONE BLOOD LEVEL; HUMAN; JAPANESE (PEOPLE); LIPID BLOOD LEVEL; LIPID METABOLISM; MALE; METABOLIC REGULATION; MIDDLE AGED; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PULSE RATE; SYSTOLIC BLOOD PRESSURE; VOMITING; WEIGHT REDUCTION; AGED; AGONISTS; BLOOD; BODY MASS; CHEMICALLY INDUCED; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FOLLOW UP; HYPERGLYCEMIA; JAPAN; METABOLISM; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; ANTI-OBESITY AGENTS; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; JAPAN; MALE; MIDDLE AGED; NAUSEA; OBESITY; PEPTIDES; VENOMS; WEIGHT LOSS;

EID: 84899670912     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ14-0009     Document Type: Article

References (9)

1. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, et al. (2005) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28: 1083-1091.
2. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, et al. (1997) Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 273: E981-988.
3. Schirra J, Goke B (2005) The physiological role of GLP-1 in human: incretin, ileal brake or more? Regul Pept 128: 109-115.
4. Moreno C, Mistry M, Roman RJ (2002) Renal effects of glucagon-like peptide in rats. Eur J Pharmacol 434: 163-167.
5. Hirata K, Kume S, Araki S, Sakaguchi M, Chin-Kanasaki M, et al. (2009) Exendin-4 has an antihypertensive effect in salt-sensitive mice model. Biochem Biophys Res Commun 380: 44-49.
6. Richter G, Feddersen O, Wagner U, Barth P, Göke R, et al. (1993) GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery. Am J Physiol 265: L374-L381.
7. Koska J, Schwartz EA, Mullin MP, Schwenke DC, Reaven PD (2010) Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recentonset type 2 diabetes. Diabetes Care 33: 1028-1030.
8. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, et al. (2008) Exenatide effects on diabetes, obesity, cardiovascular risk factors in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 24: 275-286.
9. Fujishima Y, Maeda N, Inoue K, et al. (2012) Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes. Cardiovasc Diabetol 11: 107.